Inpatients who had close contact with influenza patients were given oseltamivir (75 mg 26 capsule once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children) for 27 3 days as post-exposure prophylaxis (PEP). The index influenza patients were 28 prescribed a neuraminidase inhibitor and were immediately discharged or transferred 29 to isolation rooms. Protective efficacy of oseltamivir for 3 days was 93% for all 30 influenza patients (95% CI, 53%-99%; P=0.023) and it was 94% for patients with 31 influenza A (95% CI, 61%-99%; P=0.017), which are comparable to those of oseltamivir 32 for 7 to 10 days as PEP. (98 words) 
24 Summary 25
Inpatients who had close contact with influenza patients were given oseltamivir (75 mg 26 capsule once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children) for 27 3 days as post-exposure prophylaxis (PEP). The index influenza patients were 28 prescribed a neuraminidase inhibitor and were immediately discharged or transferred 29 to isolation rooms. Protective efficacy of oseltamivir for 3 days was 93% for all 30 influenza patients (95% CI, 53%-99%; P=0.023) and it was 94% for patients with 31 influenza A (95% CI, 61%-99%; P=0.017), which are comparable to those of oseltamivir 32 for 7 to 10 days as PEP. (98 words) 33
Introduction 37
Influenza is a common respiratory disease that results in death of about 30,000 38 to 49,000 people in the United States every year 1 . A number of nosocomial influenza 39 outbreaks in hospitals have been reported 2 . Therefore, prevention of nosocomial 40 transmission of influenza is important. Post-exposure prophylaxis (PEP) using 41 oseltamivir was shown to be effective for reducing secondary spread of influenza in 42 families 3, 4 and in pediatric wards 5 . Oseltamivir as a 75 mg capsule once daily for 43 adults and at a dose of 2 mg/kg (maximum of 75 mg) once daily for children for 7 to 10 44 days has generally been used for PEP 3-5 . 45 In this study, index cases in which influenza developed during hospitalization 46 were immediately discharged or transferred to isolation rooms, and persons who were inclose contact with the index influenza patients were administered oseltamivir for 3 days 48 as PEP. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Fisher's exact test at the level of significance of 5%. Protective efficacy and its 95% 84 confidence interval (CI) were also computed by calculating relative risk and its 95% CI 85 first and then subtracting each of them from 1. Ethical approval for this study was 86 4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 (Table 1) . Two patients for whom PEP failed to prevent influenza A infection had 108 impaired renal function (creatinine clearance of 10 to 30 ml/min): one patient took 109 oseltamivir only on the first day and developed influenza on the following day, and the 110 other patient took oseltamivir on the first and third days and developed influenza on 111 the fifth day. Seven index patients were diagnosed as having influenza B, and none of 112 the close contacts, both those who received PEP and those who did not, became infected 113 (Table 1 ). The overall protective efficacy of the 3-day regimen of oseltamivir for PEP 114 was 93% (95% CI, 53%-99%; P = 0.023) ( Several studies have been conducted on the effectiveness of PEP with 119 oseltamivir using 7 to 10-day regimens 3-6 . In our hospital, patients who developed 120 influenza during hospitalization have been separated into a private room immediately 121 after diagnosis for preventing influenza transmission. This led us to the idea that the 122 period for administration of PEP with oseltamivir could be shortened to less than 7-10 123 without PEP in our hospital are summarized in Table 2 7 . The data shown in Table 2  131   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 suggest that oseltamivir was effective in preventing onset of influenza A after exposure 132 to three subtypes of influenza A viruses. 133
In previous studies, protective efficacy of oseltamivir was shown to be 89% 4 134 and 68% 3 in households and 89% 5 in pediatric wards. Protective efficacy of 135 oseltamivir in this study was 93% for all of the influenza patients and 94% for the 136 patients with influenza A, indicating the effectiveness of the 3-day regimen of 137 oseltamivir for PEP. 138 PEP with oseltamivir for two patients in this study who had impaired renal 139 function failed to prevent influenza infection. Although an every-other-day schedule of 140 oseltamivir has been recommended for patients with impaired renal function 8 , 141 prescription of oseltamivir on the first and third days might not be sufficient for the 142 3-day regimen of oseltamivir for PEP. Additionally, because virus shedding occurs at 143 1-2 days before onset of influenza 9 , it is difficult to calculate the true interval between 144 exposure to influenza virus and oral administration of oseltamivir for the close contacts. 145
This makes it difficult to determine the causes of failure to prevent influenza by PEP. 146
Further studies are necessary. 147
There are limitations in this study. Our study was not a randomized 148 placebo-controlled study, because we could expect effectiveness of PEP from previous 149 studies 3, 4 . It is known that younger people are more frequently affected than elderly 150 people by influenza 10 . Therefore, the effectiveness of PEP might be potentially 151 overestimated because the persons in the non-PEP group were younger than those in 152 the PEP-group. Because there was a more than 10-fold difference in the numbers of 153 patients in the PEP and non-PEP groups, there might be potential biases including 154 vaccine status, which was not investigated in this study. 155   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 In conclusion, protective efficacy of the 3-day regimen of oseltamivir for PEP in 156 preventing nosocomial transmission of influenza is comparable to that of 7 to 10-day 157 regimens, provided that index cases are immediately separated from contacts. The 158 3-day regimen of oseltamivir has an advantage over 7 to 10-day regimens in terms of 159 economics of health care. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 
